

Sensitive droplet digital PCR method for detection of cell free DNA from patients with metastatic melanoma

Oncotarget

8, 78890-78900

DOI: [10.18632/oncotarget.20354](https://doi.org/10.18632/oncotarget.20354)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Optimizing Amplification of the GC-Rich TERT Promoter Region Using 7-Deaza-dGTP for Droplet Digital PCR Quantification of TERT Promoter Mutations. <i>Clinical Chemistry</i> , 2018, 64, 745-747.	1.5	18
2	Droplet Digital PCR for Mutation Detection in Formalin-Fixed, Paraffin-Embedded Melanoma Tissues. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 240-252.	1.2	32
3	An Update Regarding the Molecular Genetics of Melanocytic Neoplasms and the Current Applications of Molecular Genetic Technologies in Their Diagnosis and Treatment. <i>Clinics in Laboratory Medicine</i> , 2018, 38, 385-399.	0.7	1
4	Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. <i>BMC Cancer</i> , 2018, 18, 726.	1.1	77
5	<i>TERT</i> gene: its function and dysregulation in cancer. <i>Journal of Clinical Pathology</i> , 2019, 72, 281-284.	1.0	63
6	Telomerase reverse transcriptase alterations in human cancers: Diagnosis, prognosis, and therapeutic implications. <i>Cancer Cytopathology</i> , 2019, 127, 275-277.	1.4	0
7	Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 418-426.	1.2	18
8	ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab. <i>Scientific Reports</i> , 2019, 9, 17471.	1.6	26
9	Pathogenic TERT promoter variants in telomere diseases. <i>Genetics in Medicine</i> , 2019, 21, 1594-1602.	1.1	37
10	Development of Novel Mutation-Specific Droplet Digital PCR Assays Detecting TERT Promoter Mutations in Tumor and Plasma Samples. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 274-285.	1.2	46
11	Monitoring Melanoma Using Circulating Free DNA. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 1-12.	3.3	26
12	Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma. <i>Molecular Oncology</i> , 2019, 13, 171-184.	2.1	44
13	Detection of cell-free circulating BRAF ^{V600E} by droplet digital polymerase chain reaction in patients with and without melanoma under dermatological surveillance. <i>British Journal of Dermatology</i> , 2020, 182, 382-389.	1.4	7
14	The Role of Liquid Biopsies in Detecting Molecular Tumor Biomarkers in Brain Cancer Patients. <i>Cancers</i> , 2020, 12, 1831.	1.7	29
15	Development of Sensitive Droplet Digital PCR Assays for Detecting Urinary TERT Promoter Mutations as Non-Invasive Biomarkers for Detection of Urothelial Cancer. <i>Cancers</i> , 2020, 12, 3541.	1.7	27
16	Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. <i>Cancers</i> , 2020, 12, 2228.	1.7	22
17	Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients. <i>Scientific Reports</i> , 2020, 10, 18682.	1.6	40
18	Human Telomerase Reverse Transcriptase Gene Promoter Mutation in Serum of Patients with Hepatocellular Carcinoma. <i>Oncology</i> , 2020, 98, 311-317.	0.9	10

#	ARTICLE	IF	CITATIONS
19	The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 113.	1.6	52
20	Circulating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant Melanoma. <i>JCO Precision Oncology</i> , 2020, 4, 20-31.	1.5	19
21	Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells. <i>British Journal of Cancer</i> , 2020, 122, 1059-1067.	2.9	41
22	Detection of Gene Mutations in Liquid Biopsy of Melanoma Patients: Overview and Future Perspectives. <i>Current Treatment Options in Oncology</i> , 2020, 21, 19.	1.3	3
23	Biomarkers for Melanoma. , 2020, , 73-104.		0
24	Interplay between TERT promoter mutations and methylation culminates in chromatin accessibility and TERT expression. <i>PLoS ONE</i> , 2020, 15, e0231418.	1.1	15
25	Droplet-digital PCR reveals frequent mutations in TERT promoter region in breast fibroadenomas and phyllodes tumours, irrespective of the presence of MED12 mutations. <i>British Journal of Cancer</i> , 2021, 124, 466-473.	2.9	7
26	<i>TERT</i> Promoter Mutation Analysis for Blood-Based Diagnosis and Monitoring of Gliomas. <i>Clinical Cancer Research</i> , 2021, 27, 169-178.	3.2	50
27	Circulating tumour DNA and melanoma survival: A systematic literature review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103187.	2.0	17
28	Human telomerase reverse transcriptase and telomeres in cancer. <i>Journal of Current Oncology</i> , 2021, 4, 1.	0.2	0
29	Isolation and Quantification of Plasma Circulating Tumor DNA from Melanoma Patients. <i>Methods in Molecular Biology</i> , 2021, 2265, 247-263.	0.4	0
31	Human TERT promoter mutations as a prognostic biomarker in glioma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1007-1017.	1.2	21
32	Post-treatment cell-free DNA as a predictive biomarker in molecular-targeted therapy of hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2021, 56, 456-469.	2.3	11
33	Droplet digital PCR assay for detecting TERT promoter mutations in patients with glioma. <i>Brain Tumor Pathology</i> , 2021, 38, 201-209.	1.1	10
34	FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoring. <i>Gynecologic Oncology</i> , 2021, 162, 413-420.	0.6	11
35	Liquid Biopsy in Melanoma: Significance in Diagnostics, Prediction and Treatment Monitoring. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9714.	1.8	20
37	Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies. <i>Oncotarget</i> , 2019, 10, 113-122.	0.8	23
38	Biomarkers for Melanoma. , 2019, , 1-32.		0

#	ARTICLE	IF	CITATIONS
40	Nano pom-poms prepared exosomes enable highly specific cancer biomarker detection. <i>Communications Biology</i> , 2022, 5, .	2.0	16
41	Cell-Free DNA as a Prognostic Biomarker for Monitoring Muscle-Invasive Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11732.	1.8	6
42	Interference-free and simultaneous quantification of three breast cancer-related DNAs in multiple biological fluids using excitation-emission matrix fluorescence spectroscopy combined with second-order calibration method. <i>Microchemical Journal</i> , 2023, 191, 108776.	2.3	1